New form of Roche's Esbriet approved in Europe for lung disorder
Roche said a new Esbriet tablet formulation was approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.
Esbriet has been shown to slow the progression of IPF, and the new tablet formulation reduces the number of pills patients need to take, the Swiss drugmaker said in a statement on Tuesday.
(Reporting by Silke Koltrowitz; Editing by Michael Shields)
Esbriet has been shown to slow the progression of IPF, and the new tablet formulation reduces the number of pills patients need to take, the Swiss drugmaker said in a statement on Tuesday.
(Reporting by Silke Koltrowitz; Editing by Michael Shields)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd